Myrrh attenuates oxidative and inflammatory processes in acetic acid-induced ulcerative colitis

AMAL JAMIL FATANI[1], FATIMA SALIH ALROJAYEE[2], MIHIR YOGESHKUMAR PARMAR[1],
HATEM MUSTAFA ABUOHASHISH[1,3], MOHAMMED MAHBOOBUDDIN AHMED[1] and SALIM SALIH AL-REJAIE[1]

[1]Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451;
[2]Department of Internal Medicine, Medical School, Al Maareefa Colleges, Riyadh 11461;
[3]Department of Biomedical Dental Sciences, College of Dentistry, University of Dammam, Dammam 31441, Saudi Arabia

Abstract. The pathogenesis of ulcerative colitis (UC) has been associated with a weakened antioxidant capacity and increased inflammatory processes. *Myrrh* is traditionally used for the treatment of inflammatory diseases due to its antioxidant and anti-inflammatory properties. The present study aimed to evaluate the effects of *myrrh* on an experimental rat model of UC. UC was induced in rats using acetic acid (AA) after pre-treatment with *myrrh* (125, 250 or 500 mg/kg/day) or mesalazine (MES; 300 mg/kg/day) for 7 days. The levels of various inflammatory cytokines, prostaglandin E_2 (PGE_2) and nitric oxide (NO) in the rat colon tissues were assessed. In addition, the colonic levels of thiobarbituric acid reactive substances (TBARS) and non-protein sulfhydryl groups (NP-SH), as well as the activities of superoxide dismutase (SOD) and catalase (CAT), were estimated. Furthermore, total protein (TP) contents and the levels of DNA and RNA were measured, and histopathological changes in colonic tissues were analyzed. The results indicated that the levels of pro-inflammatory cytokines, PGE_2, NO and TBARS were markedly increased. By contrast, the levels of interleukin-10, NP-SH, TP and nucleic acids, and the enzymatic activities of SOD and CAT were significantly decreased in the AA model group. In addition, pretreatment with *myrrh* and MES was able to attenuate the impaired oxidative stress response and upregulation of inflammatory biomarkers. Furthermore, the enzymatic activities of SOD and CAT were near to normal in the *myrrh* and MES pretreated groups. The ability of *myrrh* to protect against UC was further confirmed by histopathological analysis, and the high dose of *myrrh* exerted an effect comparable to MES. In conclusion, the results of the present study suggested that *myrrh* has potent therapeutic value in the amelioration of experimental colitis in laboratory animals by downregulating the expression of proinflammatory mediators and improving endogenous antioxidative activities.

Introduction

Inflammatory bowel diseases (IBDs) comprise ulcerative colitis (UC) and Crohn's disease (1), both of which have a high incidence in developed countries and severely affect the quality of life of patients worldwide (2). IBDs, which are complex and multifactorial diseases caused by diverse pathophysiological mechanisms, have numerous clinical manifestations, including abdominal pain, diarrhea, blood in the stool and weight loss (1). Persistent UC has been associated with an increased risk of developing colorectal cancer by ~10-fold (3). UC is characterized by excessive inflammation and oxidative stress (4,5), which is considered a key factor in the pathogenesis and perpetuation of mucosal damage. Pro-inflammatory cytokines are secreted by macrophages and are responsible for the generation of reactive oxygen species (ROS), which activate the oxidative stress response and thus serve a vital role in the development and maintenance of IBD (6,7). It has been demonstrated that oxidative injury results from the overproduction of free radicals, which leads to the lipid peroxidation (LPO) of membranes and the impairment of cellular proteins and nucleic acids (8). In addition, the generation of ROS and subsequent LPO reduces the cellular antioxidant capacity, which may lead to colonic inflammation (5).

Nitric oxide (NO), an intracellular mediator released by inducible nitric oxide synthase, is able to interact with free radicals to precipitate tissue damage (9). Prostaglandin E_2 (PGE_2) is a pro-inflammatory mediator in the colon, and its upregulation has been associated with the inflammatory process (10). Various murine models of colitis have been developed over the past 20 years and are indispensable tools for elucidating the mechanisms underlying IBD pathogenesis, as well as for assaying potential therapeutics (11). The acetic acid (AA)-induced colitis model, which is similar to human UC in terms of its histological features, has been widely used to investigate the effects of various herbal therapies on experimental colitis (12,13).

Correspondence to: Professor Salim Salih Al-Rejaie, Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, 21 Abdullah Road, Riyadh 11451, Saudi Arabia
E-mail: rejaie@ksu.edu.sa

The genus *Commiphora* (Burseraceae), which includes >150 plant species, is distributed in the tropical and subtropical regions, in particular within northeastern Africa, southern Arabia and India (14). *Commiphora molmol* Engl. is the main plant used in the production of *myrrh*, which is a oleo-gum-resin (OGR) made from dried tree sap that is traditionally used as a perfume, incense or embalming ointment (15). Previous studies have reported the beneficial effects of *myrrh*, which include anti-inflammatory, antispasmodic, antirheumatic, antipyretic, antiseptic and antihistaminic properties (16-18). In addition, purified metabolites of *myrrh* crude extracts have been investigated for antiproliferative, antimicrobial, hepatoprotective and cardiovascular properties (19). Experimentally, *myrrh* has demonstrated antigastric ulcer (20), anti-oxidative, cytotoxic and non-mutagenic properties in various studies (21,22). Su *et al* (23) reported that *myrrh* significantly inhibited the production of PGE_2 in carrageenan-induced paw edema in mice and exhibited potent anti-inflammatory effects. Therefore, the present study aimed to evaluate the ability of *myrrh* to protect against AA-induced UC in a rat model by measuring potential oxidative markers and inflammatory mediators known to damage the colonic tissues.

Materials and methods

Animals. The current study was performed using 36 male Wistar albino rats (age, 12 weeks; weight, 250-280 g) that were obtained from the Experimental Animal Care Center of King Saud University (Riyadh, Saudi Arabia). The rats were maintained at 25˚C under a 12-h light/dark cycle with *ad libitum* access to Purina rat chow (Grain Silos and Flour Mills Organization, Riyadh, Saudi Arabia) and water. All experimental and euthanasia procedures were performed in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals (NIH Publications No. 80-23; 1996), as well as the Ethical Guidelines of the Experimental Animal Care Center of King Saud University.

Plant material and phytochemical screening. Authenticated *myrrh* was purchased from the local market in Riyadh, Saudi Arabia. For the purpose of maintaining experimental institutional records, the voucher specimen of the *myrrh* OGR was housed in the Herbarium at the College of Pharmacy of King Saud University. Chemical tests to identify the constituents of *myrrh* were performed using the aqueous extract, according to a standard procedure (24,25). A yield of 9.72% essential oil was obtained by steam distillation (23.17%) from the volatile oil. The presence of terpenes, sesquiterpenes, ester, cuminic, aldehyde and eugenol was detected.

Chemicals. Mesalazine (MES) was obtained from Shire (Lexington, MA, USA). The thiobarbituric acid reactive substances (TBARS) assay kit (0801192) was purchased from ZeptoMetrix Corp. (Buffalo, NY, USA). Tumor necrosis factor-α (TNF-α; RTA00), interleukin (IL)-1β (RLB00), IL-6 (R6000B), IL-10 (M1000B), PGE_2 (KGE004B) and NO (KGE001) ELISA kits were purchased from R&D Systems, Inc. (Minneapolis, MN, USA). All other chemicals used were of analytical reagent grade.

Experimental procedure. The rats were randomly allocated into five groups (6 rats per group), as follows: i) Control; ii) AA model; iii) *myrrh* (125 mg/kg/day) plus AA; iv) *myrrh* (250 mg/kg/day) plus AA; v) *myrrh* (500 mg/kg/day) plus AA; and vi) MES (300 mg/kg/day) plus AA. MES was used as a positive control against which to compare the effect of *myrrh* on UC. Pretreatment with *myrrh* or MES was conducted for 7 consecutive days by gavage. The doses used in the present study were selected based on an earlier study (20). At 24 h after the final treatment, UC was induced in all AA groups by administration of AA. After 1 day, the rats were sacrificed by decapitation under deep ether anesthesia (10 ml/l air), and 5-6-cm specimens of the rat colons were dissected, washed with saline solution and weighed. A small 5-μm-thick cross section of the colon tissue from each group was fixed in 10% formaldehyde solution for histopathological analysis. The remaining colonic tissues were maintained at -75˚C for biochemical analysis.

Induction of UC. Experimental induction of UC in the rat colons was performed according to a previous study (26), with minor modifications. Briefly, the rats were transrectally administered 2 ml 4% AA solution (v/v; Merck Millipore, Darmstadt, Germany) under light ether anesthesia (5 ml/l air) using a 2.7-mm soft pediatric catheter. Following AA administration, the rats were held horizontally for 2 min to prevent AA leakage. The control rats underwent the same procedure using an equal volume of normal saline instead of AA solution.

Analysis of the adherent colonic mucus concentration. The concentration of colon adherent mucus was estimated according to a method described previously (27). Briefly, small 5-μm-thick sections of the rat colonic tissues were transferred immediately following weighing to a mixture of 1% Alcian blue and 0.16 mol/l sucrose solution (pH 5) for 24 h. The sucrose solution was used to rinse the excess dye, after which the dye bound to the colonic wall mucus was extracted using 0.5 mol/l $MgCl_2$ and mixed with diethyl ether (1:1 ratio). The sample was then centrifuged at 1,800 x g for 15 min at room temperature and the absorbance of the aqueous layer was detected at 580 nm using a Pharmacia-LKB UV-M II spectrophotometer (GE Healthcare Life Sciences, Marlborough, MA, USA) and a standard curve. Subsequently, the quantity of Alcian blue extracted in μg/g of the wet colon was determined.

Determination of MDA levels in the rat colons. The levels of malondialdehyde (MDA), an LPO product, in the rat colon tissues were detected using the TBARS assay kit. Briefly, 100 μl colon tissue homogenate was mixed with 2.5 ml kit reaction buffer, followed by heating at 95˚C for 1 h. The sample was left to cool, centrifuged at 1,800 x g for 15 min at room temperature, and then a Pharmacia-LKB UV-M II spectrophotometer was used to measure the absorbance of the supernatant at 532 nm using a standard curve. The MDA levels in the colonic tissue are expressed in terms of nm/mg protein.

Determination of non-protein sulfhydryl groups (NP-SH) concentration in the rat colons. The colonic concentration of NP-SH was determined according to the method described by Sedlak and Lindsay (28). Briefly, the homogenate was mixed

Figure 1. Effect of myrrh on the (A) weight/length ratio and (B) mucus content (mg/g) of colonic tissue from AA-induced ulcerative colitis rats. Data are expressed as the mean ± standard error of the mean (n=6) and analyzed using one-way analysis of variance followed by Student-Newman-Keuls multiple comparisons test. The AA group was compared with the control group, while the myrrh and MES-treated groups were compared with the AA group. *P<0.05 and **P<0.01 vs. the AA group. AA, acetic acid; MES, mesalazine.

with 1 ml 50% trichloroacetic acid (TCA), followed by intermittent shaking for 10-15 min and centrifugation at 1,350 x g for 15 min at room temperature. The supernatant was mixed with 0.4 mol/l Tris buffer (pH 8.9) in a ratio of 1:2, followed by the addition of 0.1 ml DTNB. The absorbance of the mixture was measured within 5 min at 412 nm using a Pharmacia-LKB UV-M II spectrophotometer and a standard curve.

Determination of superoxide dismutase (SOD) and catalase (CAT) activities in the rat colons. To obtain the post-mitochrondrial supernatant, 200 mg colon tissue was homogenized in 2.0 ml of 50 mM phosphate buffered saline (pH 7.4) using a Pyrex glass pestle tissue grinder. Homogenates were centrifuged at 1,000 x g for 10 min at 4˚C to separate the nuclei and unbroken cells. Pellets were discarded and the supernatant was again centrifuged at 12,000 x g for 20 min at 4˚C. The enzymatic activity of the antioxidant enzyme SOD was measured in the post-mitochondrial supernatant of the colon homogenate according to a previous study by Kono (29). Briefly, superoxide anions generated by hydroxylamine hydrochloride oxidation mediated the reduction of nitro-blue tetrazolium to a blue formazan, which was then measured at 560 nm under aerobic conditions. SOD is known to inhibit nitro-blue tetrazolium reduction, and thus the extent of inhibition was used as a measure of SOD activity, which is expressed as units/mg protein (30). The enzymatic activity of CAT was measured using a method described previously (31). Briefly, the post-mitochondrial supernatant of the colon homogenate was mixed with 50 mmol/l phosphate buffer (pH 7.0) and 20 mmol/l H_2O_2. The enzymatic activity of CAT was then determined according to the decrease in absorbance at 240 nm, and is expressed in terms of units/mg protein.

Determination of DNA, RNA and total protein (TP) levels in the rat colons. The DNA and RNA concentrations in the rat colon tissues were estimated according to a previously described method by Bregman (32). Briefly, the homogenized colon tissues were suspended in 5 ml of 10% ice-cold TCA, after which the samples were centrifuged at 450 x g for 3 min at room temperature and the resulting pellets were extracted twice using 95% ethanol. Next, the nucleic acid content was extracted using 5% TCA. For DNA quantification, diphenylamine reagent was added to the extracts, and the resulting

blue color was measured at 600 nm. For RNA determination, orcinol reagent was added to the extracts and the intensity of the green color was measured at 660 nm. In addition, the Lowry method (33) was used to determine the TP content in the colon tissues, using bovine plasma albumin (BDH Chemicals, Poole, UK) as a standard.

Determination of levels of inflammatory biomarkers in the rat colon tissues. The levels of TNF-α, IL-10, IL-1β, IL-6, PGE_2 and NO in the rat colon tissues were determined using ELISA kits, according to a previous study by Mousavizadeh *et al* (26). The results are expressed as pg/mg protein.

Histopathological analysis of UC. Cross sections of the rat colon tissues were fixed in 10% formaldehyde solution, embedded in paraffin wax blocks and cut into 5-μm sections using a microtome. Samples were then stained with hematoxylin and eosin, mounted and observed under a light microscope. Histopathological sections were graded with scores of 0-4 according to inflammatory cellular infiltration, surface ulceration and necrosis, edema and hyperemia, and goblet cell hyperplasia. The scores demonstrated the percentage of damage or active changes, as follows: Score of 1, <25%; score of 2, <50%; score of 3, <75%; and score of 4 , >75% damage or active changes. The total score for the degree of colonic inflammation was determined, as follows: <4, minimal inflammatory changes; 4-8, mild inflammatory changes; 9-12, moderate inflammatory changes; and 13-16, severe inflammatory changes.

Statistical analysis. Data are expressed as the mean ± standard error of the mean. Statistical analyses involved one-way analysis of variance followed by Student-Newman-Keuls post-hoc test, and were performed using GraphPad Prism software, version 5 (GraphPad Software, Inc., La Jolla, CA, USA). P<0.05 was considered to indicate a statistically significant difference.

Results

Effect of myrrh on colon weight/length ratio and mucus content in rats with AA-induced UC. The mean colonic weights were significantly increased in the AA group, as compared with the control group (P<0.01). As shown in Fig. 1A, 7 days of

Figure 2. Effect of myrrh on the colonic levels of TNF-α, IL-1β, IL-6 and IL-10 in rats with AA-induced ulcerative colitis. Data are expressed as the mean ± standard error of the mean (n=6) and were analyzed using one-way analysis of variance, followed by Student-Newman-Keuls multiple comparisons test. The AA model group was compared with the control group, while the myrrh and MES-treated groups were compared with the AA group. *P<0.05 and **P<0.01 vs. the AA group. TNF-α, tumor necrosis factor-α; IL, interleukin; AA, acetic acid; MES, mesalazine.


Figure 3. Effect of myrrh on colonic tissue levels of (A) TBARS and (B) NP-SH, and on the activities of (C) SOD and (D) CAT in rats with AA-induced ulcerative colitis. Data are expressed as the mean ± standard error of the mean (n=6) and were analyzed using one-way analysis of variance followed by Student-Newman-Keuls multiple comparisons test. The AA group was compared with the control group, while the myrrh and MES-pretreated groups were compared with the AA group. *P<0.05 and **P<0.01 vs. the AA group. TBARS, thiobarbituric acid reactive substances; NP-SH, sulfhydryl groups; SOD, superoxide dismutase; CAT, catalase; AA, acetic acid; MES, mesalazine.

pretreatment with various doses of *myrrh* or 300 mg/kg/day MES resulted in a significant decline in the mean colon weights, as compared with the AA group (P<0.01). In addition, the rat colon mucus content was significantly decreased in the AA group, as compared with the control group (P<0.01). Pretreatment with a higher dose of *myrrh* (500 mg/kg/day) or 300 mg/kg/day MES significantly increased the mucus content of the rat colons, as compared with the AA group (P<0.05; Fig. 1B). These results suggest that *myrrh* has an anti-inflammatory and protective role against colon weight increase and gastric mucus depletion.

Effect of myrrh on the colonic levels of inflammatory cytokines in AA-induced UC rats. In the AA group, the levels of the pro-inflammatory cytokines TNF-α, IL-1β and IL-6 were significantly increased, while the levels of the anti-inflammatory cytokine IL-10 were significantly decreased, as compared with the control group (all P<0.01; Fig. 2). In the 250 and 500 mg/kg/day *myrrh* and MES pretreated groups, the levels of TNF-α, IL-1β and IL-6 were significantly decreased, as compared with the AA group (P<0.05 and P<0.01). However, in the 125 mg/kg/day *myrrh* group, only the levels of TNF-α and IL-1β, but not IL-6, were significantly decreased, as compared with the AA group. Furthermore, the levels of IL-10 were significantly increased in the 250 and 500 mg/kg/day *myrrh* and MES pretreated groups, as compared with the AA group (P<0.05; Fig. 2). These results demonstrated the anti-inflammatory property

Table I. Effect of myrrh on the colonic levels of DNA, RNA and TP in rats with AA-induced ulcerative colitis.

Group	DNA	RNA	TP
Control	524.7±33.03	360.8±31.12	3.4±0.22
AA	192±20.38[a]	159.1±20.75[a]	1.31±0.19[a]
Myrrh (mg/kg/day)			
125	288.6±56.64	194.9±27.09	1.62±0.25
250	359.3±51.33	225.3±17.13	1.9±0.25
500	467.6±57.67[b]	309.7±33.51[b]	2.82±0.33[c]
MES (300 mg/kg/day)	473.7±76.87[b]	345.2±43.07[b]	2.96±0.3[c]

Data are expressed as the mean ± standard error of the mean (n=6) and were analyzed using one-way analysis of variance followed by Student-Newman-Keuls multiple comparisons test. [a]$P<0.01$ vs. the control group; [b]$P<0.01$ and [c]$P<0.05$ vs. the AA group. TP, total protein; AA, acetic acid; MES, mesalazine.


Figure 4. Effect of myrrh on the colonic tissue levels of (A) PGE_2 and (B) NO in rats with AA-induced ulcerative colitis. Data are expressed as the mean ± standard error of the mean (n=6) and were analyzed using one-way analysis of variance, followed by Student-Newman-Keuls multiple comparisons test. The AA group was compared with the control group and the myrrh and MES-pretreated groups were compared with the AA group. *$P<0.05$ vs. the AA group. PGE_2, prostaglandin E_2; NO, nitric oxide; AA, acetic acid; MES, mesalazine.

of *myrrh*, as *myrrh* pretreatment inhibited the expression of colonic proinflammatory cytokines.

Effect of myrrh on the colonic levels of TBARS and NP-SH, and on the activities of SOD and CAT in AA-induced UC rats. At 24 h following AA administration, TBARS levels were significantly increased in the AA group, as compared with the control rats ($P<0.01$). However, pretreatment with 250 and 500 mg/kg/day *myrrh* or with MES resulted in a significant decline in TBARS levels, as compared with the AA group ($P<0.01$; Fig. 3A). In addition, the levels of NP-SH were significantly decreased in the colon tissues of AA group rats, as compared with the control group ($P<0.01$). By contrast, the levels of NP-SH were significantly increased in rats pretreated with high doses of *myrrh* (250 and 500 mg/kg) or 300 mg/kg MES, as compared with the AA group rats ($P<0.05$; Fig. 3B). The results also indicated that the activities of the antioxidative enzymes SOD and CAT were significantly inhibited in the colons of AA-treated rats, as compared with those in control rats ($P<0.01$). Pretreatment with 500 mg/kg/day *myrrh* and MES resulted in significant increases in SOD and CAT activities, as compared with the AA group ($P<0.05$; Fig. 3C and D). These results demonstrated the antioxidative effect of *myrrh*, as *myrrh* pretreatment induced a marked reduction in TBARS levels, increased NP-SH and enhanced the enzymatic activities of SOD and CAT.

Effect of myrrh on colonic levels of nucleic acids and TP content in AA-induced UC rats. The levels of DNA, RNA and TP in the rat colon tissues were significantly decreased in the rats administered AA, as compared with the control rats ($P<0.01$). Pretreatment with *myrrh* (500 mg/kg) and MES resulted in significant increases in the levels of DNA ($P<0.01$), RNA ($P<0.01$) and TP ($P<0.05$), as compared with the AA group (Table I). These dose-dependent improvements in nucleic acid levels demonstrated the cytoprotective effects of *myrrh*.

Effect of myrrh on colonic levels of PGE_2 and NO in AA-induced UC rats. PGE_2 and NO levels were significantly increased in the colonic cells of rats administered AA, as compared with the control rats ($P<0.01$). After 7 days of pretreatment with *myrrh* (500 mg/kg) or MES, a significant decrease was observed in the levels of PGE_2 and NO in rat colon tissues, as compared with those in the AA group ($P<0.05$; Fig. 4). These results suggested the anti-inflammatory potential of *myrrh*, as *myrrh* pretreatment induced a marked inhibition of the elevated levels of PGE_2 and NO in colon tissue.

Effect of myrrh on histopathological changes in the colons of AA-induced UC rats. As shown in Table II and Fig. 5, a histopathological analysis of rat colon sections revealed minimal

Table II. Effect of myrrh on histopathological changes in the colonic tissues of rats with AA-induced ulcerative colitis.

Group	Inflammatory cell infiltration	Surface ulceration and necrosis	Edema and hyperemia	Goblet cell hyperplasia	Total score
Control	0	0	0	0	0
AA	4	4	4	3	15
Myrrh (mg/kg/day)					
125	3	3	2	1	9
250	2	2	2	2	8
500	2	0	1	0	3
MES (300 mg/kg/day)	1	1	1	0	3

Sections were scored for inflammatory cell infiltration, surface ulceration and necrosis, edema and hyperemia and goblet cell hyperplasia, as follows: 1, <25% damage or active changes; 2, <50% damage or active changes; 3, <75% damage or active changes; and 4, >75% damage or active changes. A total score of <4 indicated minimal inflammatory changes, a score of 4-8 indicated mild inflammatory changes, a score of 9-12 indicated moderate inflammatory changes and a score of 13-16 indicated severe inflammatory changes. AA, acetic acid; MES, mesalazine.


Figure 5. Histopathological examination of colonic sections (Left panels, magnification x10; right panels, magnification x20). (A) Minimal surface necrosis and ulceration (arrows) with no inflammatory cell infiltration, edema or hyperemia was observed in the control group. (B) Severe surface ulceration, necrosis, edema, hyperemia and inflammatory cell infiltration (arrows) was observed in the acetic acid-treated group. (C) Moderate surface necrosis, ulceration, edema, hyperemia and inflammatory cell infiltration (arrows) was observed in the 125 mg/kg/day myrrh-treated group. (D) Mild surface necrosis, ulceration, inflammatory cell infiltration, edema and hyperemia (arrows) was observed in the 250 mg/kg/day myrrh-treated group. (E) No evidence of surface ulceration or necrosis and minimal inflammatory cell infiltration, edema and hyperemia (arrows) was observed in the 500 mg/kg/day myrrh-treated group. (F) Minimal focal surface necrosis, ulceration, edema, hyperemia and inflammatory changes (arrows) were observed in the 300 mg/kg/day mesalazine-treated group.

inflammatory cell infiltration, surface necrosis and ulceration, as well as no evidence of edema, hyperemia or goblet cell hyperplasia, in the colons of the control group rats. Therefore, the clinical diagnosis was unremarkable pathological changes (Fig. 5A). Conversely, histopathological analysis in the AA group demonstrated diffused severe inflammatory cell infiltration with marked surface ulceration, necrosis, edema and hyperemia, as well as moderate goblet cell hyperplasia, and the clinical diagnosis was diffused severe inflammatory changes (Fig. 5B). *Myrrh* pretreatment appeared to exert a

dose-dependent effect on the AA-induced histopathological changes in the rat colons. In rats pretreated with 125 mg/kg/day *myrrh*, diffuse moderate inflammatory cell infiltration with focal moderate surface ulceration, necrosis, edema and hyperemia, as well as mild focal goblet cell hyperplasia, were observed, and the clinical diagnosis was focal moderate inflammatory changes (Fig. 5C). In the 250 mg/kg/day *myrrh* group, diffused mild inflammatory cell infiltration with focal surface necrosis and ulceration and moderate edema and hyperemia, as well as mild goblet cell hyperplasia, were

observed, and the clinical diagnosis was focal mild inflammatory changes (Fig. 5D). In the 500 mg/kg/day *myrrh* group, the analysis revealed diffused mild inflammatory cell infiltration with minimal edema and hyperemia, with the absence of surface necrosis, ulceration and goblet cell hyperplasia. The clinical diagnosis for the 500 mg/kg/day *myrrh* group was diffused minimal inflammatory changes (Fig. 5E). Similarly, pretreatment with 300 mg/kg/day MES resulted in minimal focal inflammatory changes, necrosis, ulceration, edema, hyperemia and goblet cell hyperplasia. The clinical diagnosis of this group was diffused minimal inflammatory changes (Fig. 5F).

Discussion

The present study aimed to investigate the protective effects of *myrrh* in a rat model of AA-induced UC. The AA-induced UC model, which is similar to human UC in terms of histological features, has been used in various previous studies (12,34). The histopathological analysis performed in the present study demonstrated that AA treatment resulted in disruption of the entire colonic mucosa, erosion, ulceration, congestion, inflammation and necrosis. Pretreatment with *myrrh* at three different doses (125, 250 or 500 mg/kg/day) for 7 days was shown to preserve the functional cytoarchitecture of the colon to varying extents. In addition, *myrrh* markedly protected against AA-induced loss of the colonic mucosal content and prevented colonic oxidative and inflammatory responses to AA in a dose-dependent manner. The present study also compared the anti-ulcerogenic effect of *myrrh* with a standard drug, MES. The effect of MES pretreatment was similar to that observed for the 500 mg/kg/day *myrrh* pretreatment.

Under normal physiological conditions, the mucosa of the colon contains relatively low levels of endogenous antioxidants. Oxidative stress may inhibit the endogenous defense systems that regulate ROS production (35). High levels of ROS lead to oxidative stress and DNA damage due to an imbalance between innate and exogenous antioxidants and ROS (36,37). In addition, it may promote the infiltration of leukocytes into the damaged area, the rupture of the colonic barrier, and the release of inflammatory mediators, including cytokines and arachidonic acid metabolites (38,39). In the present study, the rectal administration of AA significantly increased the weight of the rat colon, and this was associated with severe tissue ulceration, inflammatory cell infiltration, necrosis and goblet cell hyperplasia, as demonstrated by the histopathological analysis. These results are consistent with those reported in previous studies using the same animal model (40,41). Defects in the colonic mucosal barrier and functions are among the etiological factors that characterize IBDs (42). In the present study, the protective colonic mucus was markedly altered by AA, which is in line with earlier studies conducted in our labs (43,44). Pretreatment with *myrrh* at various doses for 7 days significantly reduced the colon weight and inhibited colonic wall mucus depletion.

Oxidative stress is known to serve a major role in the initiation and progression of IBD (45,46). A previous study reported vascular dilatation and white blood cell accumulation in an AA-induced model of IBD, which was associated with

an increased blood flow and production of ROS (47). ROS attack cellular macromolecules, thereby disrupting epithelial cell integrity and hindering mucosal recovery, in particular in patients with an impaired endogenous defense system (48). Furthermore, the superoxide anion radical, hydrogen peroxide and hydroxyl radicals, which are secreted by neutrophils and phagocytes, accumulate in the inflammatory lesion, leading to destabilization of the cell membrane, cell death via LPO, and damage to tissue proteins and DNA (49,50). TBARS, which are markers of LPO, interact with DNA and proteins leading to pathological changes (51). The present study demonstrated that *myrrh* was able to significantly reduce the levels of TBARS in the colonic tissues of rats administered AA, thereby disrupting the feedback loop and attenuating damage to colonic tissues. Endogenous antioxidants, such as NP-SH, and antioxidant enzymes, including SOD and CAT (52), serve a major role in preventing excessive free radical generation under pathogenic conditions. In the present study, the concentration of NP-SH and the activities of SOD and CAT were significantly reduced in the colon tissues of AA-treated rats. In addition, the levels of critical cellular macro- and micro-molecules, including nucleic acids and proteins, were decreased in the AA group rats. These results were consistent with our previous findings (43,44), and indicated that AA was able to exert harmful effects on cellular macromolecules, impair epithelial cell integrity and hinder mucosal recovery.

IBD is a complex multi-factorial intestinal inflammatory disease, involving immunological, genetic and environmental factors (53). Pro-inflammatory mediators are able to modulate the mucosal immune system and disrupt the epithelial integrity by promoting the infiltration of neutrophils and macrophages (54). The migration of granulocytes and other leukocytes to the inflamed mucosa and superficial ulcers results in the overproduction of pro-inflammatory cytokines (55,56), which is an indicator of the disease severity. In the coordinated network of inflammatory response, TNF-α serves an important signaling role in the inflammatory cascade following its secretion. Specifically, it activates monocytes, macrophages and intestinal immune cells in order to produce PGE_2, proteases and chemotactic cytokines (57). IL-6 is a pleiotropic cytokine that has a central role in immune regulation and inflammation (58). IL-6-activated macrophages and colon epithelial cells secrete inflammatory cytokines, including TNF-α and IL-1β, that contribute to the development of colitis (59). In the present study, the levels of IL-1β, TNF-α, IL-6, NO and PGE_2 were significantly increased in colon tissues of AA-treated rats. These results suggested that the colons of the AA-treated rats were inflamed, which was supported by the histopathological results. In addition, these results were consistent with those of previous experimental and clinical studies (27,40,60,61).

In accordance with previous studies (62,63), the antioxidant effects of *myrrh* were also demonstrated in the present study. The levels of NP-SH and the activities of SOD and CAT in rat colonic tissues were increased in *myrrh*-treated rats in a dose-dependent manner, with higher *myrrh* doses resulting in a greater effect. The cytoprotective and antioxidant effects of *myrrh* demonstrated in the present study may have been due to the presence of several pharmacologically active constituents. The distribution of 51 constituents and medical applications of

Commiphora were reviewed in 2003 by El Ashry *et al* (19). *myrrh* contains volatile oil, which in turn consists of heerabolene, a-cadinene, elemol, eugenol, cuminaldehyde, terpenes (such as furanodiene, furanodienone, curzerenone, lindestrene, 2-methoxyfuranodiene and 3-epi-alpha-amyrin), and various other compounds (64). In addition, myrcene, a-camphorene and various steroids, including Z-guggulsterol and guggulsterol I, II and III, have been detected (65), while a previous study reported that tannins were also found in *myrrh* (66). Therefore, these antioxidative constituents may, at least in part, be responsible for the protective effect of *myrrh* pretreatment against AA-induced UC. Furthermore, the anti-inflammatory properties of *myrrh* have previously been reported (67). Consistent with this, the present study observed that AA treatment resulted in a marked reduction in the colonic levels of pro-inflammatory cytokines, including IL-1β, IL-6 and TNF-α, which are principally responsible for causing oxidative damage (68). Therefore, it may be hypothesized that the anti-inflammatory effects of *myrrh* are regulated by its antioxidative activities.

In conclusion, the results of the present study provided support for the beneficial effects of *myrrh* against AA-induced experimental colitis. The protective properties of *myrrh* may be attributed to its ability to inhibit free radical production and potentiate the endogenous enzymatic or nonenzymatic antioxidant system. Furthermore, *myrrh* was shown to decrease the levels of inflammatory mediators, thus suggesting that it may have a role as an anti-inflammatory compound. The results of the present study suggest that *myrrh* may be a promising novel candidate compound for the treatment of IBDs.

Acknowledgements

References

1. Safarpour AR, Hosseini SV and Mehrabani D: Epidemiology of inflammatory bowel diseases in iran and Asia; a mini review. Iran J Med Sci 38 (Suppl 2): S140-S149, 2013.
2. Xavier RJ and Podolsky DK: Unravelling the pathogenesis of inflammatory bowel disease. Nature 448: 427-434, 2007.
3. Mehrabani D, Tabei ST, Heydari SJ, Shamsina SJ, Shokrpour N, Amini M, Masoumi SJ, Julaee H, Farahmand M and Manafi A: Cancer occurrence in Fars Province, Southern Iran. Iran Red Crescent Med J 10: 314-322, 2008.
4. Cetinkaya A, Bulbuloglu E, Kantarceken B, Ciralik H, Kurutas EB, Buyukbese MA and Gumusalan Y: Effects of L-carnitine on oxidant/antioxidant status in acetic acid-induced colitis. Dig Dis Sci 51: 488-494, 2006.
5. Cetinkaya A, Bulbuloglu E, Kurutas EB, Ciralik H, Kantarceken B and Buyukbese MA: Beneficial effects of N-acetylcysteine on acetic acid-induced colitis in rats. Tohoku J Exp Med 206: 131-139, 2005.
6. Seo HG, Takata I, Nakamura M, Tatsumi H, Suzuki K, Fujii J and Taniguchi N: Induction of nitric oxide synthase and concomitant suppression of superoxide dismutases in experimental colitis in rats. Arch Biochem Biophys 324: 41-47, 1995.
7. Larrick JW and Wright SC: Cytotoxic mechanism of tumor necrosis factor-alpha. FASEB J 4: 3215-3223, 1990.
8. Bertevello PL, Logullo AF, Nonogaki S, Campos FM, Chiferi V, Alves CC, Torrinhas RS, Gama-Rodrigues JJ and Waitzberg DL: Immunohistochemical assessment of mucosal cytokine profile in acetic acid experimental colitis. Clinics (Sao Paulo) 60: 277-286, 2005.
9. Pacher P, Beckman JS and Liaudet L: Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87: 315-424, 2007.
10. Rachmilewitz D, Karmeli F, Okon E, Rubenstein I and Better OS: Hyperbaric oxygen: A novel modality to ameliorate experimental colitis. Gut 43: 512-518, 1998.
11. Chassaing B, Aitken JD, Malleshappa M and Vijay-Kumar M: Dextran sulfate sodium (DSS)-induced colitis in mice. Curr Protoc Immunol 104: Unit 15.25, 2014.
12. Mehrabani D, Ziaei M, Hosseini SV, Ghahramani L, Bananzadeh AM, Ashraf MJ, Amini A, Amini M and Tanideh N: The effect of calendula officinalis in therapy of acetic Acid induced ulcerative colitis in dog as an animal model. Iran Red Crescent Med J 13: 884-890, 2011.
13. Redwan el-RM and Tabll A: Camel lactoferrin markedly inhibits hepatitis C virus genotype 4 infection of human peripheral blood leukocytes. J Immunoassay Immunochem 28: 267-277, 2007.
14. Hanuš LO, Řezankab T, Dembitskya VM and Moussaieff A: *Myrrh-Commiphora* chemistry. Biomed Papers 149: 3-28, 2005.
15. Mugah JO, Chikamai BN, Mbiru SS and Casadei E: Conservation, management and utilization of plant gums, resins and essential oils. Proceedings of a Regional Conference for Africa (Nairobi, Kenya), 6-10 Oct, 1997.
16. Massoud A, El Sisi S, Salama O and Massoud A: Preliminary study of therapeutic efficacy of a new fasciolicidal drug derived from *Commiphora molmol* (*myrrh*). Am J Trop Med Hyg 65: 96-99, 2001.
17. Shalaby MA and Ashraf Hammouda AA: Analgesic, anti-inflammatory and anti-hyperlipidemic activities of *Commiphora molmol* extract (*Myrrh*) J Intercult Ethnopharmacol 3: 56-62, 2014.
18. El-Sherbiny GM and El Sherbiny ET: The effect of *Commiphora molmol* (*Myrrh*) in treatment of *Trichomoniasis vaginalis* infection. Iran Red Crescent Med J 13: 480-486, 2011.
19. El Ashry ES, Rashed N, Salama OM and Saleh A: Components, therapeutic value and uses of *myrrh*. Pharmazie 58: 163-168, 2003.
20. al-Harbi MM, Qureshi S, Raza M, Ahmed MM, Afzal M and Shah AH: Gastric antiulcer and cytoprotective effect of *Commiphora molmol* in rats. J Ethnopharmacol 55: 141-150, 1997.
21. al-Harbi MM, Qureshi S, Ahmed MM, Rafatullah S and Shah AH: Effect of *Commiphora molmol* (oleo-gum-resin) on the cytological and biochemical changes induced by cyclophosphamide in mice. Am J Chin Med 22: 77-82, 1994.
22. Qureshi S, al-Harbi MM, Ahmed MM, Raza M, Giangreco AB and Shah AH: Evaluation of the genotoxic, cytotoxic and antitumor properties of *Commiphora molmol* using normal and Ehrlich ascites carcinoma cell-bearing Swiss albino mice. Cancer Chemother Pharmacol 33: 130-138, 1993.
23. Su S, Hua Y, Wang Y, Gu W, Zhou W, Duan JA, Jiang H, Chen T and Tang Y: Evaluation of the anti-inflammatory and analgesic properties of individual and combined extracts from *Commiphora myrrha* and *Boswellia carterii*. J Ethnopharmacol 139: 649-656, 2012.
24. Sofowora A: Medicinal plants and traditional medicine in Africa. John Wiley and Sons Ltd, Chichester, 1982.
25. AOAC: Official Methods of Analysis. 15th edition. Association of Official Analytical Chemists, Inc., Arlington, Virginia, 1990.
26. Mousavizadeh K, Rahimian R, Fakhfouri G, Aslani FS and Ghafourifar P: Anti-inflammatory effects of 5-HT receptor antagonist, tropisetron on experimental colitis in rats. Eur J Clin Invest 39: 375-383, 2009.
27. Popov SV, Markov PA, Nikitina IR, Petrishev S, Smirnov V and Ovodov YS: Preventive effect of a pectic polysaccharide of the common cranberry Vaccinium oxycoccos L. on acetic acid-induced colitis in mice. World J Gastroenterol 12: 6646-6651, 2006.
28. Sedlak J and Lindsay RH: Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem 25: 192-205, 1968.
29. Kono Y: Generation of superoxide radical during autoxidation of hydroxylamine and an assay for superoxide dismutase. Arch Biochem Biophys 186: 189-195, 1978.
30. Monk LS, Fagerstedt KV and Crawford RM: Superoxide dismutase as an anaerobic polypeptide: A key Factor in recovery from oxygen deprivation in *Iris pseudacorus*? Plant Physiol 85: 1016-1020, 1987.
31. Aebi H: Catalase. In: Methods of Enzymatic Analysis. Bergmeyer HU (ed.). Academic Press, New York, pp 674-684, 1974.

32. Bregman AA: Laboratory Investigations in Cell Biology. John Wiley and Sons, New York, 1983.
33. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275, 1951.
34. Mehrabani D, Bahrami F, Hosseini SV, Ashraf MJ, Tanideh N, Rezaianzadeh A, Amini M and Amini A: The healing effect of teucrium polium in acetic acid-induced ulcerative colitis in the dog as an animal model. Middle East J Dig Dis 4: 40-47, 2012.
35. Bhattacharyya A, Chattopadhyay R, Mitra S and Crowe SE: Oxidative stress: An essential factor in the pathogenesis of gastrointestinal mucosal diseases. Physiol Rev 94: 329-354, 2014.
36. Hemnani T and Parihar MS: Reactive oxygen species and oxidative DNA damage. Indian J Physiol Pharmacol 42: 440-452, 1998.
37. Rezaie A, Parker RD and Abdollahi M: Oxidative stress and pathogenesis of inflammatory bowel disease: An epiphenomenon or the cause? Dig Dis Sci 52: 2015-2021, 2007.
38. Pavlick KP, Laroux FS, Fuseler J, Wolf RE, Gray L, Hoffman J and Grisham MB: Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease. Free Radic Biol Med 33: 311-322, 2002.
39. Grisham MB: Oxidants and free radicals in inflammatory bowel disease. Lancet 344: 859-861, 1994.
40. El-Abhar HS, Hammad LN and Gawad HS: Modulating effect of ginger extract on rats with ulcerative colitis. J Ethnopharmacol 118: 367-372, 2008.
41. Harputluoglu MM, Demirel U, Yücel N, Karadağ N, Temel I, Firat S, Ara C, Aladağ M, Karincaoğlu M and Hilmioğlu F: The effects of Gingko biloba extract on acetic acid-induced colitis in rats. Turk J Gastroenterol 17: 177-182, 2006.
42. Duerr RH: Update on the genetics of inflammatory bowel disease. J Clin Gastroenterol 37: 358-367, 2003.
43. Aleisa AM, Al-Rejaie SS, Abuohashish HM, Ola MS, Parmar MY and Ahmed MM: Pretreatment of Gymnema sylvestre revealed the protection against acetic acid-induced ulcerative colitis in rats. BMC Complement Altern Med 14: 49, 2014.
44. Al-Rejaie SS, Abuohashish HM, Al-Enazi MM, Al-Assaf AH, Parmar MY and Ahmed MM: Protective effect of naringenin on acetic acid-induced ulcerative colitis in rats. World J Gastroenterol 19: 5633-5644, 2013.
45. Patel MA, Patel PK and Patel MB: Effects of ethanol extract of Ficus bengalensis (bark) on inflammatory bowel disease. Indian J Pharmacol 42: 214-218, 2010.
46. Narushima S, Spitz DR, Oberley LW, Toyokuni S, Miyata T, Gunnett CA, Buettner GR, Zhang J, Ismail H, Lynch RG and Berg DJ: Evidence for oxidative stress in NSAID-induced colitis in IL10$^{-/-}$ mice. Free Radic Biol Med 34: 1153-1166, 2003.
47. Hartmann RM, Morgan Martins MI, Tieppo J, Fillmann HS and Marroni NP: Effect of Boswellia serrata on antioxidant status in an experimental model of colitis rats induced by acetic acid. Dig Dis Sci 57: 2038-2044, 2012.
48. Buffinton GD and Doe WF: Depleted mucosal antioxidant defences in inflammatory bowel disease. Free Radic Biol Med 19: 911-918, 1995.
49. Tüzün A, Erdil A, Inal V, Aydin A, Bağci S, Yeşilova Z, Sayal A, Karaeren N and Dağalp K: Oxidative stress and antioxidant capacity in patients with inflammatory bowel disease. Clin Biochem 35: 569-572, 2002.
50. Pravda J: Radical induction theory of ulcerative colitis. World J Gastroenterol 11: 2371-2384, 2005.
51. Ayala A, Muñoz MF and Argüelles S: Lipid peroxidation: Production, metabolism, and signaling mechanisms of malondi-aldehyde and 4-hydroxy-2-nonenal. Oxid Med Cell Longev 2014: 360438, 2014.
52. Boots AW, Haenen GR and Bast A: Health effects of quercetin: From antioxidant to nutraceutical. Eur J Pharmacol 585: 325-337, 2008.
53. Button LA, Roberts SE, Goldacre MJ, Akbari A, Rodgers SE and Williams JG: Hospitalized prevalence and 5-year mortality for IBD: Record linkage study. World J Gastroenterol 16: 431-438, 2010.
54. Grisham MB and Yamada T: Neutrophils, nitrogen oxides, and inflammatory bowel disease. Ann NY Acad Sci 664: 103-115, 1992.
55. Sartor RB: Cytokines in intestinal inflammation: Pathophysiological and clinical considerations. Gastroenterology 106: 533-539, 1994.
56. Elson CO, Sartor RB, Tennyson GS and Riddell RH: Experimental models of inflammatory bowel disease. Gastroenterology 109: 1344-1367, 1995.
57. Zhang JM and An J: Cytokines, inflammation and pain. Int Anesthesiol Clin 45: 27-37, 2007.
58. Sanchez-Munoz F, Dominguez-Lopez A and Yamamoto-Furusho JK: Role of cytokines in inflammatory bowel disease. World J Gastroenterol 14: 4280-4288, 2008.
59. Suzuki A, Hanada T, Mitsuyama K, Yoshida T, Kamizono S, Hoshino T, Kubo M, Yamashita A, Okabe M, Takeda K, et al: CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J Exp Med 193: 471-481, 2001.
60. Stucchi A, Reed K, O'Brien M, Cerda S, Andrews C, Gower A, Bushell K, Amar S, Leeman S and Becker J: A new transcription factor that regulates TNF-alpha gene expression, LITAF, is increased in intestinal tissues from patients with CD and UC. Inflamm Bowel Dis 12: 581-587, 2006.
61. Tahan G, Aytac E, Aytekin H, Gunduz F, Dogusoy G, Aydin S, Tahan V and Uzun H: Vitamin E has a dual effect of anti-inflammatory and antioxidant activities in acetic acid-induced ulcerative colitis in rats. Can J Surg 54: 333-338, 2011.
62. Ashry KM, El-Sayed YS, Khamiss RM and El-Ashmawy IM: Oxidative stress and immunotoxic effects of lead and their amelioration with myrrh (Commiphora molmol) emulsion. Food Chem Toxicol 48: 236-241, 2010.
63. Al-Rejaie SS: Effect of oleo-gum-resin on ethanol-induced hepatotoxicity in rats. J Med Sci 12: 1-9, 2012.
64. Rahman MM, Garvey M, Piddock LJ and Gibbons S: Antibacterial terpenes from the oleo-resin of Commiphora molmol (Engl.). Phytother Res 22: 1356-1360, 2008.
65. Brieskorn CH and Noble P: Three new furanogermacrenes from myrrh. Tetrahedron Lett 21: 1511-1514, 1980.
66. Dolara P, Luceri C, Ghelardini C, Monserrat C, Aiolli S, Luceri F, Lodovici M, Menichetti S and Romanelli MN: Analgesic effects of myrrh. Nature 379: 29, 1996.
67. Tariq M, Ageel AM, Al-Yahya MA, Mossa JS, Al-Said MS and Parmar NS: Anti-inflammatory activity of Commiphora molmol. Agents Actions 17: 381-382, 1986.
68. Tipton DA, Lyle B, Babich H and Dabbous MKh: In vitro cytotoxic and anti-inflammatory effects of myrrh oil on human gingival fibroblasts and epithelial cells. Toxicol In vitro 17: 301-310, 2003.